349 related articles for article (PubMed ID: 21602892)
21. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
[TBL] [Abstract][Full Text] [Related]
22. Tuberin, p27 and mTOR in different cells.
Burgstaller S; Rosner M; Lindengrün C; Hanneder M; Siegel N; Valli A; Fuchs C; Hengstschläger M
Amino Acids; 2009 Feb; 36(2):297-302. PubMed ID: 18386114
[TBL] [Abstract][Full Text] [Related]
23. Characterization of p70 S6 kinase 1 in early development of mouse embryos.
Xu XY; Zhang Z; Su WH; Zhang Y; Yu YQ; Li YX; Zong ZH; Yu BZ
Dev Dyn; 2009 Dec; 238(12):3025-34. PubMed ID: 19877273
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
[TBL] [Abstract][Full Text] [Related]
25. Activation of S6K1 (p70 ribosomal protein S6 kinase 1) requires an initial calcium-dependent priming event involving formation of a high-molecular-mass signalling complex.
Hannan KM; Thomas G; Pearson RB
Biochem J; 2003 Mar; 370(Pt 2):469-77. PubMed ID: 12429015
[TBL] [Abstract][Full Text] [Related]
26. Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition.
Hartmann B; He X; Keller F; Fischereder M; Guba M; Schmid H
Ther Drug Monit; 2013 Apr; 35(2):233-9. PubMed ID: 23503450
[TBL] [Abstract][Full Text] [Related]
27. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling.
Gao S; Duan C; Gao G; Wang X; Yang H
Int J Biochem Cell Biol; 2015 Jul; 64():25-33. PubMed ID: 25813876
[TBL] [Abstract][Full Text] [Related]
28. IKK-β mediates hydrogen peroxide induced cell death through p85 S6K1.
Jia CH; Li M; Liu J; Zhao L; Lin J; Lai PL; Zhou X; Zhang Y; Chen ZG; Li HY; Liu AL; Yang CL; Gao TM; Jiang Y; Bai XC
Cell Death Differ; 2013 Feb; 20(2):248-58. PubMed ID: 22955948
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): a tissue microarray study (TMA).
Evren S; Dermen A; Lockwood G; Fleshner N; Sweet J
Prostate; 2010 Sep; 70(13):1429-36. PubMed ID: 20687216
[TBL] [Abstract][Full Text] [Related]
30. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.
Buller CL; Loberg RD; Fan MH; Zhu Q; Park JL; Vesely E; Inoki K; Guan KL; Brosius FC
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C836-43. PubMed ID: 18650261
[TBL] [Abstract][Full Text] [Related]
31. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.
Bostner J; Karlsson E; Eding CB; Perez-Tenorio G; Franzén H; Konstantinell A; Fornander T; Nordenskjöld B; Stål O
Endocr Relat Cancer; 2015 Jun; 22(3):331-43. PubMed ID: 25972244
[TBL] [Abstract][Full Text] [Related]
32. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation.
Martin KA; Rzucidlo EM; Merenick BL; Fingar DC; Brown DJ; Wagner RJ; Powell RJ
Am J Physiol Cell Physiol; 2004 Mar; 286(3):C507-17. PubMed ID: 14592809
[TBL] [Abstract][Full Text] [Related]
33. Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway.
Cao Y; Kamioka Y; Yokoi N; Kobayashi T; Hino O; Onodera M; Mochizuki N; Nakae J
J Biol Chem; 2006 Dec; 281(52):40242-51. PubMed ID: 17077083
[TBL] [Abstract][Full Text] [Related]
34. mTOR is the rapamycin-sensitive kinase that confers mechanically-induced phosphorylation of the hydrophobic motif site Thr(389) in p70(S6k).
Hornberger TA; Sukhija KB; Wang XR; Chien S
FEBS Lett; 2007 Oct; 581(24):4562-6. PubMed ID: 17825298
[TBL] [Abstract][Full Text] [Related]
35. The immunosuppressant tributyltin oxide blocks the mTOR pathway, like rapamycin, albeit by a different mechanism.
Osman AM; van Loveren H
J Appl Toxicol; 2014 Dec; 34(12):1361-7. PubMed ID: 24375594
[TBL] [Abstract][Full Text] [Related]
36. eIF3 controls cell size independently of S6K1-activity.
Schipany K; Rosner M; Ionce L; Hengstschläger M; Kovacic B
Oncotarget; 2015 Sep; 6(27):24361-75. PubMed ID: 26172298
[TBL] [Abstract][Full Text] [Related]
37. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.
El-Hashemite N; Zhang H; Henske EP; Kwiatkowski DJ
Lancet; 2003 Apr; 361(9366):1348-9. PubMed ID: 12711473
[TBL] [Abstract][Full Text] [Related]
38. A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1.
Bachmann RA; Kim JH; Wu AL; Park IH; Chen J
J Biol Chem; 2006 Mar; 281(11):7357-63. PubMed ID: 16407298
[TBL] [Abstract][Full Text] [Related]
39. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex.
Shah OJ; Hunter T
J Biol Chem; 2004 May; 279(20):20816-23. PubMed ID: 14993219
[TBL] [Abstract][Full Text] [Related]
40. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
